EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GBA1-Associated Parkinson’s Disease Is a Distinct Entity

Aliaksandr Skrahin, Mia Horowitz, Majdolen Istaiti iD, Volha Skrahina, Jan Lukas iD, Gilad Yahalom, Mikhal E Cohen, Shoshana Revel-Vilk iD, Ozlem Goker-Alpan iD, Michal Becker-Cohen, Sharon Hassin-Baer, Per Svenningsson iD und 2 weitere

International Journal of Molecular Sciences · 28.06.2024 · 25 (13) · 7102

DOI: 10.3390/ijms25137102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.06.2024. Verfasst von Aliaksandr Skrahin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Rare Disease Consulting RCV GmbH, Leibnizstrasse 58, 10629 Berlin, Germany. Hauptthemen laut MEDLINE: Glucosylceramidase, Parkinson Disease, Mutation. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GBA1-associated Parkinson’s disease (GBA1-PD) is increasingly recognized as a distinct entity within the spectrum of parkinsonian disorders. This review explores the unique pathophysiological features, clinical progression, and genetic underpinnings that differentiate GBA1-PD from idiopathic Parkinson’s disease (iPD). GBA1-PD typically presents with earlier onset and more rapid progression, with a poor response to standard PD medications. It is marked by pronounced cognitive impairment and a higher burden of non-motor symptoms compared to iPD. Additionally, patients with GBA1-PD often exhibit a broader distribution of Lewy bodies within the brain, accentuating neurodegenerative processes. The pathogenesis of GBA1-PD is closely associated with mutations in the GBA1 gene, which encodes the lysosomal enzyme beta-glucocerebrosidase (GCase). In this review, we discuss two mechanisms by which GBA1 mutations contribute to disease development: ‘haploinsufficiency,’ where a single functional gene copy fails to produce a sufficient amount of GCase, and ‘gain of function,’ where the mutated GCase acquires harmful properties that directly impact cellular mechanisms for alpha-synuclein degradation, leading to alpha-synuclein aggregation and neuronal cell damage. Continued research is advancing our understanding of how these mechanisms contribute to the development and progression of GBA1-PD, with the ‘gain of function’ mechanism appearing to be the most plausible. This review also explores the implications of GBA1 mutations for therapeutic strategies, highlighting the need for early diagnosis and targeted interventions. Currently, small molecular chaperones have shown the most promising clinical results compared to other agents. This synthesis of clinical, pathological, and molecular aspects underscores the assertion that GBA1-PD is a distinct clinical and pathobiological PD phenotype, necessitating specific management and research approaches to better understand and treat this debilitating condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosylceramidaseParkinson DiseaseMutationHumansalpha-Synuclein

Stichwörter der Autor:innen

GBA1 variantsGBA1-associated Parkinson diseaseParkinson’s diseaseclinical presentation and coursegenotype-phenotype correlationspathophysiology and molecular mechanismstreatment options

Substanzen

GlucosylceramidaseGBA protein, humanalpha-Synuclein

Autor:innen und Institutionen

  • Rare Disease Consulting RCV GmbH, Leibnizstrasse 58, 10629 Berlin, Germany.
  • Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel Aviv University, 6997801 Ramat Aviv, Israel.
  • Gaucher Unit, Shaare Zedek Medical Center, 9103102 Jerusalem, Israel.
  • Agyany Pharma Ltd., 9695614 Jerusalem, Israel.
  • Translational Neurodegeneration Section Albrecht Kossel, Department of Neurology, University Medical Center Rostock, 18147 Rostock, Germany.
  • Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany.

ORCID-Profile: Majdolen Istaiti, Jan Lukas, Shoshana Revel-Vilk, Ozlem Goker-Alpan, Per Svenningsson, Ari Zimran

Zitieren

APA

Skrahin, A., Horowitz, M., Istaiti, M., Skrahina, V., Lukas, J., Yahalom, G., Cohen, M. E., Revel-Vilk, S., Goker-Alpan, O., Becker-Cohen, M., Hassin-Baer, S., Svenningsson, P., Rolfs, A., & Zimran, A. (2024). GBA1-Associated Parkinson’s Disease Is a Distinct Entity. International Journal of Molecular Sciences, 25(13), 7102. https://doi.org/10.3390/ijms25137102

Vancouver

Skrahin A, Horowitz M, Istaiti M, Skrahina V, Lukas J, Yahalom G, et al. GBA1-Associated Parkinson’s Disease Is a Distinct Entity. International Journal of Molecular Sciences. 2024;25(13):7102. doi:10.3390/ijms25137102

BibTeX
@article{Skrahin2024,
  author = {Skrahin, Aliaksandr and Horowitz, Mia and Istaiti, Majdolen and Skrahina, Volha and Lukas, Jan and Yahalom, Gilad and Cohen, Mikhal E and Revel-Vilk, Shoshana and Goker-Alpan, Ozlem and Becker-Cohen, Michal and Hassin-Baer, Sharon and Svenningsson, Per and Rolfs, Arndt and Zimran, Ari},
  title = {GBA1-Associated Parkinson’s Disease Is a Distinct Entity},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {13},
  pages = {7102},
  doi = {10.3390/ijms25137102}
}
Kostenlos starten →